Onco-Innovations Limited (CBOE CA: ONCO) (OTCQB: ONNVF) (Frankfurt: W1H) has announced significant progress in advancing its lead candidate ONC010 toward clinical development. The company has completed key manufacturing and preclinical steps, including the production of a 300-gram batch of the active ingredient with approximately 99.3% purity. This development is crucial for a candidate designed to inhibit Polynucleotide Kinase Phosphatase (PNKP), an enzyme involved in DNA repair pathways that cancer cells exploit to survive DNA-damaging therapies.
ONC010 combines a small-molecule PNKP inhibitor with a nanoparticle delivery system, aiming to disable cancer cells' ability to repair damage induced by treatments such as chemotherapy and radiation. By targeting PNKP, Onco-Innovations seeks to enhance the efficacy of existing cancer therapies and potentially overcome resistance mechanisms.
The company's latest update highlights several technical achievements. In addition to the high-purity active pharmaceutical ingredient (API) batch, Onco-Innovations has optimized polymer components and identified a non-tin catalyst that could improve impurity control in future manufacturing. These advancements are expected to streamline production and ensure consistent quality as the candidate moves toward regulatory filings.
Onco-Innovations is also building a regulatory pathway in Australia to support a potential First-in-Human study. During the second half of 2026, the company plans to advance bioanalytical, metabolism, ADME (absorption, distribution, metabolism, excretion), toxicology, biodistribution, and regulatory preparations. This timeline suggests a strategic focus on entering clinical trials in Australia, a country known for efficient regulatory processes.
The significance of this progress lies in the growing interest in DNA Damage Response (DDR) inhibitors as a class of cancer therapeutics. DDR pathways are critical for maintaining genomic stability, and cancer cells often rely on them to survive DNA-damaging agents. By inhibiting PNKP, ONC010 could sensitize tumors to treatment, potentially improving outcomes for patients with various cancer types. However, ONC010 is still in preclinical development, and its safety and efficacy have not yet been evaluated in humans.
Investors and stakeholders can follow the latest news and updates regarding ONNVF in the company’s newsroom at ibn.fm/ONNVF. As with any early-stage biotech, the path to market is long and uncertain, but Onco-Innovations' recent milestones indicate a methodical approach to advancing ONC010 from molecule to medicine.
